Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K. B., Johnson, M. O., Threatt, S., … Bigner, D. D. (2020). Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Desjardins, Annick, Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret O. Johnson, Stevie Threatt, Chevelle A. Bullock, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Desjardins A, Randazzo D, Chandramohan V, Peters KB, Johnson MO, Threatt S, et al. Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Desjardins, Annick, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Desjardins A, Randazzo D, Chandramohan V, Peters KB, Johnson MO, Threatt S, Bullock CA, Herndon JE, Healy P, Lipp ES, Sampson JH, Friedman AH, Friedman HS, Ashley DM, Bigner DD. Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). JOURNAL OF CLINICAL ONCOLOGY. 2020.